GlaxoSmithKline Plc (GSK)

41.09
0.49 1.20
NYSE : Health Technology
Prev Close 40.60
Open 40.94
Day Low/High 40.87 / 41.20
52 Wk Low/High 36.41 / 42.49
Volume 1.29M
Avg Volume 2.28M
Exchange NYSE
Shares Outstanding 2.49B
Market Cap 102.24B
EPS 2.00
P/E Ratio 23.84
Div & Yield 2.00 (4.86%)

Latest News

GlaxoSmithKline, CenturyLink, Health Catalyst: 'Mad Money' Lightning Round

GlaxoSmithKline, CenturyLink, Health Catalyst: 'Mad Money' Lightning Round

Jim Cramer weighs in on GlaxoSmithKline, CenturyLink, Health Catalyst, Wynn Resorts, Upland Software, Red Robin Gourmet Burgers, Enphase Energy and more.

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Jim Cramer says if you want to see the U.S. economy's strength, look to Home Depot, where the consumer's confidence and influence remains healthy.

GlaxoSmithKline Beats Q2 Profit Estimate, Sees Stronger 2019 Despite Advair Loss

GlaxoSmithKline Beats Q2 Profit Estimate, Sees Stronger 2019 Despite Advair Loss

GlaxoSmithKline posted stronger-than-expected second quarter earnings Wednesday, and lifted its full-year profit guidance, as pharmaceutical sales gains offset the loss of exclusivity of the group's Advair asthma treatment.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Nucala (mepolizumab) Autoinjector (Photo: Business Wire)

Nucala (mepolizumab) Autoinjector (Photo: Business Wire)

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer...

Thermo Fisher Scientific To Acquire Manufacturing Site In Cork, Ireland, From GSK

Thermo Fisher Scientific To Acquire Manufacturing Site In Cork, Ireland, From GSK

Expands global footprint for complex API manufacturing

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline

Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline

Let's check out the charts.

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Pfizer Could Be a Healthy Option in This Volatile Market

Pfizer Could Be a Healthy Option in This Volatile Market

The health care sector may a good place to weather this storm. Here is why and how to play it.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Stocks Hit New Lows After Early Rally as Fed Hikes Key Rate

Stocks Hit New Lows After Early Rally as Fed Hikes Key Rate

Stocks plunged Wednesday afternoon following the Federal Reserve's decision to raise rates by a quarter point.

Fed, Micron, Glaxo and Pfizer, FedEx and Facebook - 5 Things You Must Know

Fed, Micron, Glaxo and Pfizer, FedEx and Facebook - 5 Things You Must Know

U.S. stock futures rise Wednesday as investors prep for an announcement from the Federal Reserve on interest rates; Micron tumbles after a weak second-quarter sales forecast; Glaxo and Pfizer combine their consumer health businesses; FedEx slumps after lowering its outlook.

GlaxoSmithKline, Pfizer Form Consumer Healthcare Group With $13 Billion in Sales

GlaxoSmithKline, Pfizer Form Consumer Healthcare Group With $13 Billion in Sales

GlaxoSmithKline shares surged to the top of the European market Wednesday after the drugmaker said it would combine its consumer health division with U.S. rival Pfizer's to create a new division with $13 billion in annual sales.

Pfizer And GlaxoSmithKline Announce Joint Venture To Create A Premier Global Consumer Healthcare Company

Pfizer And GlaxoSmithKline Announce Joint Venture To Create A Premier Global Consumer Healthcare Company

Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Jim Cramer weighs in on Abbott, GlaxoSmithKline, Waste Management and more.

The Fed is In a Corner: Cramer's 'Mad Money' Recap (Thursday 12/7/18)

The Fed is In a Corner: Cramer's 'Mad Money' Recap (Thursday 12/7/18)

Investors are stressing about the economy and the Fed, which has little room to maneuver, Jim Cramer says.

Dow Ends Up Sharply; Stocks Rally on Easing Trade Tensions

Dow Ends Up Sharply; Stocks Rally on Easing Trade Tensions

U.S. stocks ended higher Monday after President Trump backed down from threats to impose additional tariffs on Chinese goods for 90 days while the countries work to negotiate a resolution to ongoing trade disputes.

GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro

GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro

GlaxoSmithKline said Monday that it's agreed to buy ovarian cancer drug specialists Tesaro for around $5.1 billion.

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

TheStreet Quant Rating: B (Buy)